MASLD with Sven Francque - Part 1

One in three adults has MASLD, but who actually progresses? Around 30% of adults now have steatotic liver disease, but only a small fraction will progress to cirrhosis. The clinical question is which ones. In part one of this two-part series, Pradeep Mundre speaks with Professor Sven Francque (Antwerp University Hospital), co-author of the 2024 EASL multi-society guidelines on MASLD. They work through the new nomenclature (MASLD, MASH, MetALD), why dysfunctional adiposity rather than BMI is the right lens for risk, and how to use FIB-4 as the gateway test in primary care: below 1.3 to reassure, above 2.67 to refer, gray zone...